FeesSafety
Pluang+

NRx completes validation and confirms 2-year stability for preservative-free ketamine ahead of FDA approval

Market News
19 Oct 2026, 15:30 WIB
GlobeNewsWire
View Source
Bullish
NRx completes validation and confirms 2-year stability for preservative-free ketamine ahead of FDA approval

NRx Pharmaceuticals has successfully completed the manufacturing process validation for preservative-free ketamine and confirmed two-year stability data showing the drug remains potent and sterile without preservatives. This milestone prepares NRx to supply the drug immediately upon FDA approval expected by November 10, 2026. The drug addresses shortages and has potential for treating suicidal ideation in depression. NRx aims for a labeled shelf life of three years or more, enhancing availability for hospitals and clinics.

NRx Pharmaceuticals' recent manufacturing milestone for preservative-free ketamine provides context for readers. For those tracking the health sector, as of Oct 19, 2026 18:43 WIB, 68 of 150 US health stocks on Pluang rose while 54 fell. Among notable movers, IOVA gained 1.32% to USD 13.80 with a typical hold time of 2 days, SANA also rose 1.32% to USD 2.30 with a 24-day hold, whereas SNY declined 1.28% to USD 40.09 with a much longer hold time of 94 days.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
34 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
38 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
43 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
43 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
43 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App